Inhibitor of bruton tyrosine kinase

A compound of Formula (I):

• wherein,
• W is selected from the group consisting of H, C1-6alkyl, aryl optionally substituted with halogenated C1-3alkyl or a five- to seven-membered nitrogen-containing aliphatic ring, heteroaryl, and —C(O)—R3, wherein R3 is C1-3alkyl, di(C1-3alkyl)amino, or C1-3alkoxy optionally substituted with aryl;
• X is selected from the group consisting of halo and C1-6alkyl, and X is bonded to any bondable position on the pyridone ring;
• Y is selected from the group consisting of H, halo, C1-6alkyl, and C1-3alkoxy optionally substituted with C1-3alkoxy;
• R1 and R2 are independently the same or different, and are selected from the group consisting of H, C1-3alkyl optionally substituted with C1-3alkoxy or di(C1-3alkyl)amino, C(O), S(O), and S(O)2;
• L1 and L2 are independently the same or different, and are selected from the group consisting of C1-6alkyl optionally substituted with —NR4R5, C2-3alkenyl optionally substituted with halo or optionally substituted C1-3alkyl, and C2-3alkynyl optionally substituted with C1-3alkyl, wherein the substituent of the optionally substituted C1-3alkyl is di(C1-3alkyl)amino, or a five- to seven-membered nitrogen-containing aliphatic ring;
• and
• R4 and R5 in —NR4R5 are independently the same or different, and are selected from the group consisting of H, C1-3alkyl, and C2-3alkenylcarbonyl, or one of R4 and R5, and one carbon atom in the C1-6alkyl optionally substituted with —NR4R5, together with the atom to which they are bonded, form a five- to seven-membered nitrogen-containing aliphatic ring,
• provided that when R1 is H, or C1-3alkyl optionally substituted with C1-3alkoxy or di(C1-3alkyl)amino, L1 is absent, and when R2 is H, or C1-3alkyl optionally substituted with C1-3alkoxy or di(C1-3alkyl)amino, L2 is absent,
• or a pharmaceutically acceptable salt thereof.